Home » VEGFR3/Flt-4 » VEGFR3/Flt-4 Proteins » Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

 (17 Publications)
 See All Related
Submit a Review

Images

 
There are currently no images for VEGFR3/Flt-4 (349-F4).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Binding Activity
Format
Carrier-Free

Order Details

Novus Biologicals offers 100% Guarantee

Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF Summary

Details of Functionality
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGFR3/Flt‑4 Fc Chimera at 5 μg/mL (100 μL/well) binds Recombinant Human VEGF-D (Catalog # 622-VD) with an apparent Kd <15 nM.
Source
Mouse myeloma cell line, NS0-derived human VEGFR3/Flt-4 protein
Human Flt-4
(Tyr25-Ile776) &
(Ser473-Ile776)
Accession # P35916		 IEGRDMD Human IgG1
(Pro100-Lys330) 		6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Tyr25 & Ser473
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
Gene
FLT4
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Binding Activity
Theoretical MW
112 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
145-150 kDa, 90-95 kDa and 75-80 kDa, reducing conditions
Publications
Read Publications using
349-F4 in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 200 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

  • EC 2.7.10
  • EC 2.7.10.1
  • FLT4
  • Flt-4
  • fms-related tyrosine kinase 4
  • LMPH1A
  • PCLFLT41
  • soluble VEGFR3 variant 1
  • soluble VEGFR3 variant 2
  • soluble VEGFR3 variant 3
  • Tyrosine-protein kinase receptor FLT4
  • vascular endothelial growth factor receptor 3
  • VEGF R3
  • VEGFR3
  • VEGFR-3
  • VEGFR3Fms-like tyrosine kinase 4

Background

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt‑1) and VEGFR3 (Flt‑4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt‑4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.

  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Customers Who Viewed This Item Also Viewed...

VEGF-C [HRP]
DVEC00
ELISA VEGF-C [HRP]
N/A VEGF-C [HRP]
N/A VEGF-C [HRP]
(54 Publications)
Species: Hu
Applications: ELISA
VEGF [HRP]
DVE00
N/A VEGF [HRP]
N/A VEGF [HRP]
N/A VEGF [HRP]
(686 Publications)
Species: Hu
Applications: ELISA
VEGFR2/KDR/Flk-1
Antibody [Unconjugate ...
AF644
Neutralization VEGFR2/KDR/Flk-1 Antibody [Unconjugated]
Immunohistochemistry VEGFR2/KDR/Flk-1 Antibody [Unconjugated]
Immunohistochemistry VEGFR2/KDR/Flk-1 Antibody [Unconjugated]
(3 Reviews)
(98 Publications)
Species: Mu
Applications: CyTOF-ready, Dual ISH-IHC, Flow, IHC, Neut, WB
VEGF-D [HRP]
DVED00
N/A VEGF-D [HRP]
N/A VEGF-D [HRP]
N/A VEGF-D [HRP]
(36 Publications)
Species: Hu
Applications: ELISA
VEGFR1/Flt-1
Antibody [Unconjugate
AF321
Immunohistochemistry VEGFR1/Flt-1 Antibody [Unconjugated]
Immunohistochemistry VEGFR1/Flt-1 Antibody [Unconjugated]
Western Blot VEGFR1/Flt-1 Antibody [Unconjugated]
(2 Reviews)
(73 Publications)
Species: Hu
Applications: Block, CyTOF-ready, Flow, IHC, WB
ATP Citrate Lyase
Antibody
NBP1-90267
Immunocytochemistry/ Immunofluorescence ATP Citrate Lyase Antibody
Western Blot ATP Citrate Lyase Antibody
Western Blot ATP Citrate Lyase Antibody
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, KD, WB
LYVE-1 Antibody
[Unconjugated]
AF2125
Immunohistochemistry LYVE-1 Antibody [Unconjugated]
Western Blot LYVE-1 Antibody [Unconjugated]
Immunocytochemistry/ Immunofluorescence LYVE-1 Antibody [Unconjugated]
(1 Review)
(144 Publications)
Species: Mu
Applications: Dual ISH-IHC, IHC, WB
Podoplanin
Antibody [Unconjugate
AF3244
Western Blot Podoplanin Antibody [Unconjugated]
Immunohistochemistry Podoplanin Antibody [Unconjugated]
Immunocytochemistry/ Immunofluorescence Podoplanin Antibody [Unconjugated]
(1 Review)
(74 Publications)
Species: Mu
Applications: IHC, Simple Western, WB
CD31/PECAM-1
Antibody [Unconjugate
AF3628
Immunohistochemistry CD31/PECAM-1 Antibody [Unconjugated]
Flow Cytometry CD31/PECAM-1 Antibody [Unconjugated]
Immunohistochemistry CD31/PECAM-1 Antibody [Unconjugated]
(6 Reviews)
(511 Publications)
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, ICC, IHC, Simple Western, WB
Hemoglobin alpha
Antibody - BSA Free
NB110-41083
Hemoglobin alpha Antibody - BSA Free
(12 Publications)
Species: Hu
Applications: ChIP, ELISA, ICC/IF, WB
Desmocollin-3
Antibody (765129)
MAB7265
Western Blot Desmocollin-3 Antibody (765129)
Immunohistochemistry Desmocollin-3 Antibody (765129)
(1 Review)
Species: Mu
Applications: IHC, WB
PLGF [HRP]
DPG00
N/A PLGF [HRP]
N/A PLGF [HRP]
N/A PLGF [HRP]
(79 Publications)
Species: Hu
Applications: ELISA
CD34 Antibody
[Unconjugated]
AF4117
Immunohistochemistry CD34 Antibody [Unconjugated]
(3 Reviews)
(37 Publications)
Species: Rt
Applications: IHC, WB
Recombinant Human
VEGFR3/Flt-4 Fc Chime ...
349-F4
Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF
Species: Hu
Applications: Binding Activity

Publications for VEGFR3/Flt-4 (349-F4)(17)

We have publications tested in 4 confirmed species: Human, Mouse, N/A, Porcine.

We have publications tested in 6 applications: Bioassay, ELISA (Standard), ELISA Developmet, Enzyme Assay, Neutralization, Surface Plasmon Resonance.


Filter By Application
Bioassay
(12)
ELISA (Standard)
(1)
ELISA Developmet
(1)
Enzyme Assay
(1)
Neutralization
(1)
Surface Plasmon Resonance
(1)
All Applications
Filter By Species
Human
(11)
Mouse
(2)
N/A
(1)
Porcine
(1)
All Species
Showing Publications 1 - 10 of 17. Show All 17 Publications.
Publications using 349-F4 Applications Species
Mondal, DK;Xie, C;Buraschi, S;Iozzo, RV; Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression bioRxiv : the preprint server for biology 2023-08-29 [PMID: 37693608] (Bioassay, N/A) Bioassay N/A
TM Chang, PY Chu, HY Lin, KW Huang, WC Hung, YS Shan, LT Chen, HJ Tsai PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation Journal of Biomedical Science, 2022-11-06;29(1):92. 2022-11-06 [PMID: 36336681] (Bioassay, Human, Mouse) Bioassay Human, Mouse
J Zhang, H Li, Q Wu, Y Chen, Y Deng, Z Yang, L Zhang, B Liu Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth Redox Biol, 2019-02-06;22(0):101116. 2019-02-06 [PMID: 30769285] (Neutralization, Human) Neutralization Human
SB Mamer, S Chen, JC Weddell, A Palasz, A Wittenkell, M Kumar, PI Imoukhuede Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics Sci Rep, 2017-11-27;7(1):16439. 2017-11-27 [PMID: 29180757] (Surface Plasmon Resonance, Human) Surface Plasmon Resonance Human
Marc G Achen Differential receptor binding and regulatory mechanisms for the lymphangiogenic growth factors VEGF-C and VEGF-D J. Biol. Chem., 2016-11-16;0(0):. 2016-11-16 [PMID: 27852824] (Bioassay) Bioassay
Terrance G Johns Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma Sarcoma, 2016-10-16;2016(0):3484673. 2016-10-16 [PMID: 27822137] (Bioassay, Human) Bioassay Human
Kyu-Yeon Han, Jin-Hong Chang, Hyun Lee, Dimitri T Azar Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Investigative Ophthalmology & Visual Science, 2016-06-01;0(0):1552-5783. 2016-06-01 [PMID: 27327585] (Enzyme Assay, Human) Enzyme Assay Human
Harris , Nicole C, Davydova , Natalia, Roufail , Sally, Paquet-Fifield , Sophie, Paavonen , Karri, Karnezis , Tara, Zhang , You-Fang, Sato , Teruhiko, Rothacker , Julie, Nice , Edouard, Stacker , Steven A, Achen , Marc G The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology. J Biol Chem, 2013-02-12;288(12):8176-86. 2013-02-12 [PMID: 23404505] (Bioassay, Human) Bioassay Human
Tabata T, Petitt M, Fang-Hoover J, Rivera J, Nozawa N, Shiboski S, Inoue N, Pereira L Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model. Am J Pathol, 2012-09-07;181(5):1540-59. 2012-09-07 [PMID: 22959908] (Bioassay, Human) Bioassay Human
Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis, 2009-12-01;30(12):2005-13. 2009-12-01 [PMID: 19825968] (Bioassay, Human) Bioassay Human
Show All 17 Publications.

Reviews for VEGFR3/Flt-4 (349-F4) (0)

There are no reviews for VEGFR3/Flt-4 (349-F4). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for VEGFR3/Flt-4 (349-F4) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional VEGFR3/Flt-4 Products

Blogs on VEGFR3/Flt-4

There are no specific blogs for VEGFR3/Flt-4, but you can read our latest blog posts.
Read our latest blog and use the new citation tool on bio-techne.com

Customers Who Bought This Also Bought

Contact Information

Product PDFs

  PDF SDS
  PDF Datasheet
  Request CofA

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF and receive a gift card or discount.


Bioinformatics

Gene Symbol FLT4
Uniprot